Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer

PURPOSE: To investigate the survival outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line novel androgen receptor axis-targeted therapies (ARATs) and prognostic factors for patient survival. METHODS: This retrospective study obtained data from 202 patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Tseng, Chi-Shin, Yang, Jui-Han, Huang, Shi-Wei, Wang, Yu-Jen, Chen, Chung-Hsin, Pu, Yeong-Shiau, Cheng, Jason Chia-Hsien, Huang, Chao-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10283214/
https://www.ncbi.nlm.nih.gov/pubmed/37340337
http://dx.doi.org/10.1186/s12885-023-10885-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10283214/
https://www.ncbi.nlm.nih.gov/pubmed/37340337
http://dx.doi.org/10.1186/s12885-023-10885-4

Ejemplares similares